<VariationArchive RecordType="classified" VariationID="52" VariationName="NM_022098.4(XPNPEP3):c.931_934del (p.Asn311fs)" VariationType="Deletion" Accession="VCV000000052" Version="2" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-12-25" DateCreated="2021-08-11" MostRecentSubmission="2021-08-11">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="15091" VariationID="52">
      <GeneList>
        <Gene Symbol="XPNPEP3" FullName="X-prolyl aminopeptidase 3" GeneID="63929" HGNC_ID="HGNC:28052" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>22q13.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="40857148" stop="40932815" display_start="40857148" display_stop="40932815" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" start="41253084" stop="41328822" display_start="41253084" display_stop="41328822" Strand="+" />
          </Location>
          <OMIM>613553</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_022098.4(XPNPEP3):c.931_934del (p.Asn311fs)</Name>
      <CanonicalSPDI>NC_000022.11:40909194:CAAACA:CA</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>22q13.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="40909195" stop="40909198" display_start="40909195" display_stop="40909198" variantLength="4" positionVCF="40909194" referenceAlleleVCF="TCAAA" alternateAlleleVCF="T" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" start="41305199" stop="41305202" display_start="41305199" display_stop="41305202" variantLength="4" positionVCF="41305198" referenceAlleleVCF="TCAAA" alternateAlleleVCF="T" />
      </Location>
      <ProteinChange>N311fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_028221.1" sequenceAccession="NG_028221" sequenceVersion="1" change="g.57117_57120del">
            <Expression>NG_028221.1:g.57117_57120del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_022098.4" sequenceAccession="NM_022098" sequenceVersion="4" change="c.931_934del" MANESelect="true">
            <Expression>NM_022098.4:c.931_934del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_071381.1" sequenceAccession="NP_071381" sequenceVersion="1" change="p.Asn311fs">
            <Expression>NP_071381.1:p.Asn311fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000022.10" sequenceAccession="NC_000022" sequenceVersion="10" change="g.41305201_41305204del" Assembly="GRCh37">
            <Expression>NC_000022.10:g.41305201_41305204del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000022.11" sequenceAccession="NC_000022" sequenceVersion="11" change="g.40909197_40909200del" Assembly="GRCh38">
            <Expression>NC_000022.11:g.40909197_40909200del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="Allelic variant" ID="613553.0002" DB="OMIM" />
        <XRef Type="rs" ID="2146270895" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_022098.4(XPNPEP3):c.931_934del (p.Asn311fs) AND Nephronophthisis-like nephropathy 1" Accession="RCV000000069" Version="4">
        <ClassifiedConditionList TraitSetID="26">
          <ClassifiedCondition DB="MedGen" ID="C3150419">Nephronophthisis-like nephropathy 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2010-03-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2010-03-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2021-08-11" MostRecentSubmission="2021-08-11">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">20179356</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="26" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="9598" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Nephronophthisis-like nephropathy 1</ElementValue>
                <XRef ID="Nephronophthisis-like+nephropathy+1/8986" DB="Genetic Alliance" />
                <XRef ID="MONDO:0013163" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">NPHPL1</ElementValue>
                <XRef Type="MIM" ID="613159" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">The nephronophthisis (NPH) phenotype is characterized by reduced renal concentrating ability, chronic tubulointerstitial nephritis, cystic renal disease, and progression to end-stage renal disease (ESRD) before age 30 years. Three age-based clinical subtypes are recognized: infantile, juvenile, and adolescent/adult. Infantile NPH can present in utero with oligohydramnios sequence (limb contractures, pulmonary hypoplasia, and facial dysmorphisms) or postnatally with renal manifestations that progress to ESRD before age 3 years. Juvenile NPH, the most prevalent subtype, typically presents with polydipsia and polyuria, growth retardation, chronic iron-resistant anemia, or other findings related to chronic kidney disease (CKD). Hypertension is typically absent due to salt wasting. ESRD develops at a median age of 13 years. Ultrasound findings are increased echogenicity, reduced corticomedullary differentiation, and renal cysts (in 50% of affected individuals). Histologic findings include tubulointerstitial fibrosis, thickened and disrupted tubular basement membrane, sporadic corticomedullary cysts, and normal or reduced kidney size. Adolescent/adult NPH is clinically similar to juvenile NPH, but ESRD develops at a median age of 19 years. Within a subtype, inter- and intrafamilial variability in rate of progression to ESRD is considerable. Approximately 80%-90% of individuals with the NPH phenotype have no extrarenal features (i.e., they have isolated NPH); ~10%-20% have extrarenal manifestations that constitute a recognizable syndrome (e.g., Joubert syndrome, Bardet-Biedl syndrome, Jeune syndrome and related skeletal disorders, Meckel-Gruber syndrome, Senior-LÃ¸ken syndrome, Leber congenital amaurosis, COACH syndrome, and oculomotor apraxia, Cogan type).</Attribute>
                <XRef ID="NBK368475" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="18180" />
                <XRef ID="18180" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">27336129</ID>
                <ID Source="BookShelf">NBK368475</ID>
              </Citation>
              <XRef ID="655" DB="Orphanet" />
              <XRef ID="C3150419" DB="MedGen" />
              <XRef ID="MONDO:0013163" DB="MONDO" />
              <XRef Type="MIM" ID="613159" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="20212" SubmissionDate="2021-08-09" DateLastUpdated="2021-08-11" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="613553.0002_NEPHRONOPHTHISIS-LIKE NEPHROPATHY 1" title="XPNPEP3, 4-BP DEL, 931AACA_NEPHRONOPHTHISIS-LIKE NEPHROPATHY 1" />
        <ClinVarAccession Accession="SCV000020212" DateUpdated="2021-08-11" DateCreated="2013-04-04" Type="SCV" Version="3" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2010-03-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In 2 affected sibs from a consanguineous Turkish family with nephronophthisis-like nephropathy-1 (NPHPL1; 613159), O'Toole et al. (2010) identified a homozygous 4-bp deletion (931delAACA) in exon 6 of the XPNPEP3 gene, resulting in premature termination within the predicted prolidase domain, which is the catalytic domain. The mutation was not found in 150 European controls or in 83 Turkish controls. The mutation was predicted to result in complete loss of protein function. The patients had a severe disorder, with end-stage renal disease by 8 and 9 years of age, respectively. Renal ultrasound and renal histology demonstrated nephronophthisis. In addition, both affected individuals showed a mitochondrial disorder, with isolated complex I deficiency activity in muscle and had seizures, mental retardation, and hypertrophic dilated cardiomyopathy. One had chronic pancreatitis with pancreatic cysts, while the other had hepatic involvement.</Attribute>
              <Citation>
                <ID Source="PubMed">20179356</ID>
              </Citation>
              <XRef DB="OMIM" ID="613159" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="XPNPEP3" />
          </GeneList>
          <Name>XPNPEP3, 4-BP DEL, 931AACA</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">4-BP DEL, 931AACA</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="613553.0002" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">NEPHRONOPHTHISIS-LIKE NEPHROPATHY 1</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="20212" TraitType="Disease" MappingType="Name" MappingValue="NEPHRONOPHTHISIS-LIKE NEPHROPATHY 1" MappingRef="Preferred">
        <MedGen CUI="C3150419" Name="Nephronophthisis-like nephropathy 1" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

